ASCO生活指南(2022.3版)驱动因素改变的IV期非小细胞肺癌的治疗

Check for updatesTherapy for Stage IV Non-Small-Cell LungCancer With Driver Alterations:ASCO LivingGuideline,Version 2022.30r99Ishmael A.Jaiyesimi,DO,MS;Dwight H.Owen,MD,MS>;Nofisat Ismaila,MD,MSc;Elizabeth Blanchard,MD;Paul Celano,MD;Narjust Florez,MD;Dharamvir Jain,MD;and Navneet Singh,MD,DMidelineupdate6Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequentchange in clinical practice.Living guidelines are updated on a regular schedule by a standing expert panel thattrasystematically reviews the health literature on a continuous basis:as described in the ASCO GuidelinesMethodology Manual.ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation forClinical Practice Guidelines.Living Guidelines and updates are not intended to substitute for independentprofessional judgment of the treating provider and do not account for individual variation among patients.Seeappendix for disclaimers and other important information (Appendix I and Appendix 2).Updates are publishedregularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.Clin Oncol 00.2023 by American Society of Clinical OncologyBACKGROUNDaccepted treatment.Although the benefitof bevacizumabIn 2022,ASCO launched living clinical practiceand osimertinib has not demonstrated improvement overguidelines for systemic therapy for patients with stageosimertinib alone,there are many ongoing trials testingASSOCIATEDI non-small-cell lung cancer (NSCLC)with!andthis combination in the metastatic setting.A summary ofCONTENTwithout driver alterations,2 and both have beenthe results of the updated literature search is provided inSee accompanyingupdated recently.34 On the basis of routine literatureAppendix Table A2 (online only).Evidence supportingarticle doi:10.1200/searches (until November 3.2022).this version of theunchanged recommendations is reviewed in previousJC0.22.00824stage IV NSCLC with driver alterations living guidelinepublications of this guideline.14Refer to Appendix TableAppendixreviews new evidence to assess if recommendationsA3 (online only)for the full list of recommendations.Author affiliationsare up to date.ASCO believes that cancer clinical trials are vital toand supportinformation (ifinform medical decisions and improve cancer care andapplicable)appearRESULTSthat all patients should have the opportunity toat the end of thisFour studies were identified in the literature search.s participate.article.After careful review of the identified publications.theAccepted on January10,2023andExpert Panel (Appendix Table Al,online only)con-ADDITIONAL RESOURCESpublished atcluded that the study results do not affect the 2022.2 Additional information includinga supplement,clinicalascopubs.org/joumal/guideline recommendations.4 Pemetrexed is already a tools,and resources can be found at www.asco.org/jco on February 21,preferred chemotherapy for nonsquamous NSCLC.Thethoracic-cancer-guidelines.Patient information